pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1299 |
Genomic Coordinates | chr9: 40929010 - 40929092 |
Synonyms | MIRN1299, hsa-mir-1299, MIR1299 |
Description | Homo sapiens miR-1299 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1299 | ||||||||||||||||||
Sequence | 62| UUCUGGAAUUCUGUGUGAGGGA |83 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Illumina | ||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ZNF37A | ||||||||||||||||||||
Synonyms | KOX21, ZNF37 | ||||||||||||||||||||
Description | zinc finger protein 37A | ||||||||||||||||||||
Transcript | NM_001007094 | ||||||||||||||||||||
Other Transcripts | NM_001178101 , NM_003421 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ZNF37A | |||||||||||||||||||||
3'UTR of ZNF37A (miRNA target sites are highlighted) |
>ZNF37A|NM_001007094|3'UTR 1 AGTCAGAACTTTGTAGAACACAGAACATAAAGGGTGAGAGAAATCTGTTAATATAATGATAATGAGAACACCTTTGCCCT 81 GAAGTCAGTTCTCACAGTATAGAAGAGAACTTAAAGAGGGAAAAAACAATATGAAGATAGGGAATGCAGGAAAACATTAT 161 TCTGGAATTTGGACCATACACTATGTTACAAAACTAAAAGTGGAAAAAACTTATTGGTGAATGAATATAGGAAACATTTT 241 GCCCAATGCCACTCTTCATTAAACATCAGAGAATTCACACGGGGTGAAACCTGGGTCAGCATCCCTAGGTTGAGAAGGGA 321 TGCATTTTTCTGCTACTACTACAGTTTCACAGAATACCTGAGAAGACACACTTGGAGAAACCTTTTGGGTGTAATGAATG 401 TGGGAAAACCTTTCATCAGAAGTCAGCTCTAATTGTTCACCACAGAACTCATATAAGACAGAAACCCTATGGGTGTAATG 481 AATGTGGAAAATCATTCTGTGTGAAGTCAAGAGGCCAGAGAAAATGCACAAACTGTAGGAAACTATAGGAAAGCATTTAC 561 TATGAGGTTATATTTTATGGAGTATATGTAATAAGAAGTAGCTTCTCAGTGAACATCAGATAGTAGAGAAAGTATTTTTA 641 ACTGTATCCAATGTGTGGATGTTTTAAGTTAAAATCTAAATTTAATATAGAACAGAGGTGTTGAGTTGCAGGATATCTAG 721 CAATTTAAGAAAATGTGGAAAAAATATTTTTATTGAGAAATAGCATTTTACTTTGTTAATATCTAGTTTAGTTCATTGTC 801 AAGACTGCTATTTTCTAAGAGACTTCTAAAGACGCCACTCAAGCCAATGGCTATAAGTAGTTCAAAGGTTTATTGCTTAG 881 CCATATGAAAAATAAGGGAAGATTTTTTAGCAAGGGGACCCACAAACAAGAGTGCTCTTGTATGTCCAGAAGAAAGAGAA 961 AGACCATCAATCAGGGGCCATAGTACAGGAGCCCACCAGCAGGATTTTTGAATAATCCTAGGGCAGACTAAATTCAGACG 1041 ACCCATCTCAGAATGGTGGATCAAAGCAGCAAGTCAATTTGCCTTGTATGCAACTTATGAGGATTAGTAGAAGAGAGTGG 1121 GTCCAGATTTCTGGTGGTTTCTGCCCTGCAGATGTCTAACACATAAGCCAGGACATTCTGCTGTGAGTGACTTATTGTAC 1201 CCAACTCTATTTCTCTCCATACTGAAACATGTCTTTCATAGGTGATACAACTTTTTAAAATGTATGTGTAGATATAACTT 1281 AAATATGGAGCTTTCAAAAAGCACAAATAGGCTGGACATGGTGGCTCATGCCTGTAATCCCAGTACTTTGGGAGGCTGAG 1361 GTGGGCAAATCACCTGAGGTCAGGAGTTCCAGACCAGCCTGGCCAACATGATGAAACCCTGTCTCTACTAAAAATACAAA 1441 AATTAGCCGGGCATGGTGGTGCACATCGGTAGTCCTGGCTACTAGAGAGGTTGAGGTGGGAGGATCACTTGAACCTGGGA 1521 GGTGGGGGTTTCAGTGAGCTGAGATCATGCCACTGCACTCCAGCCTGAGTGACAGAGAGAGATTCAAAAAACAAAAAAAA 1601 AGCAAAAATATACTTTGCTATTGGGTAAGGTATAGTAGTTGGCAGCAGAATGGACCCATTGAGGATAACTATAAAATTAC 1681 AGAAAATATTTAAATGCAACTTATTGCTATAGAAGCAAAGAGGACTAAAGGGCAAAATTCTAGAGAGTGGTAAATCTCAG 1761 AAAGCACAAGCATAAAATGCAGCTCTGGGGGCCCTTTCCACTTCTGGCTATAGGGAAGAACCTGAATACTGAACTTGATT 1841 CAGGCAGAGGACCATAACCTGGGGGTCAGGGGAAGGCATGGGGGGGACCAGAAACCAGAAGAACAATCAAGACTGCAATG 1921 AAAAAAATGGATACATTAGGAGCTTCAAACACATATAATTTCTCAAGAAATTTCCAGATGTCTCATGCTGCATAGGGCAG 2001 GAGCCTGAAAAGCTAATTTGAGAAGATAATAAGTAGGATTTTTGTTTTGTTTTGCATTTTGCAGTACAAAGGAGAAATGA 2081 TTAGAACTTAGGAAGTGCCAGTGGGTTGGTGAACATGCCATCAGTAAAAGCCCTGGAAACAAGGTCATACTAGAGATTGG 2161 TTGTGCCTTGTCACAACTGCAAACAATACCTGAGTGGAGTATTCAAAAACTTGCTTAGAAAGAAAACTCTAGGAACAGAT 2241 GGCTTCACTGAAGTTATTCCAAATATTTAAGAAATAATACCAGGCTTTTATAAACTTTTCTAGAAGAAAAAAGATGGAAC 2321 TTTTCCAATTCAGTTTTTGAGGCCAGTACAACCTTGATAACAAAACCTAAAAAAAAAACAACAAAAAAACCCATAAAGCT 2401 ATAGACCAAAGTCTCATAGATTTAGATGCAAAATCCTAAAATTGAAAAAAACATCTAGCCATATCCATAAACTATATCAT 2481 CACCAAGAGATGTTTATTAGGGCAATCAAAAGATTTATTATTTTAAAAAAATCAGTGTGGACTTCCATTCCTCTTTCTTT 2561 TGATTCCCCCCTTTGACTTTTCATGTATCTCTCCTGCCTTCCTTCCCCAGAGTGGAGGAGTTAGACTTGCCTCGTGGGAT 2641 GAGAGGAGTTGTGGCTTTGTGTCTGCTGGCACCAAGAGGGCTGAGGGTGAGGTGTGGAAGGGACAGGGGGAGGAGATGGG 2721 CAGCATTGTTGAGAGATTGGTAACACTGAGCAAATAAATATGTTGAGAATGATGACAGCAAGATTTCTCCATTAGAGAAG 2801 GTATTTATAAAAATAGGAATGAGGAGAGCTAGAAAACCTGGAGTGTGGCATTAGAATAGAACTCATATCTTTTAAATATA 2881 TAGGAACAAATAAATAAATTGTTGTGTGTGCACATATGCATATATTTTGTGTTCATTCTACTGAGAGGACCTAAACACAA 2961 TGACACCTCAGTAACAGTAAGCACACCAACTGCCAAGTTATTAGTTCCTAAATACTATCCACAAAAAAGGGGAACAGGGA 3041 TGATTCCTAGTCAGAGATTGGGAGAAATACAAGATGAGCCTGAATCATCTCATGTACCTGACAGTAAGAAAATACTCTGG 3121 CTGGTCTCAGTGGCTCATGTCTGTAATTCTAGCATGTTAGAAGGTCAAGGTGGGTGGGTTGCTTGAGCTCAGGAGTTTGA 3201 GACCAGCCTGGGCAACATGGCACAATTGTCTCTACAAAAAATACAAAAATTAGCCAGGCATGGTGGCATGCACCTGTAGT 3281 CCGAGGTACTCAGGAGGCAGAGACGTGGGAGGATCGCTTGAGCCTGGGAGATTGAGGCTGCACTGAGCTGTGATCGTGCC 3361 ACTGTACTCTAGCCTGGAAGACAGAGTGAGACCCCATCTCAGGAAAAAAGAAAAAAAAAAAGATGTCATTCAGCAGGTTA 3441 ATGGATAAACTGTGGAACATCCAGAAAACTTTAACATTCTTCAAAGAAATAGAAAACACAATCCTAAAATTTATATGGGA 3521 ACCACAAAAGACTTAGAATAGTCAGCTATCCTGAGCAAAAGGAATCAAACTGGAGGAATCATATTACCTGACTTCCAATT 3601 ATTCAACAGAGCTACAGTAACCAAAACAGCATGATACTGGCATAACAACAGACACATAGGAACAGTATAGACAACCCAGA 3681 AACAAATTCATACATCTATGGTGACCACTTTTGACAAAGGAATGAAGAACATACACTGGGGAAAAGATAATGTCTTTAAT 3761 AAATGGTGCTGGGAAAACTGGATATCCATATGCAGAAGAATGAAACTAGACCCCCATCTCTTAGCATATACAAAAATCAA 3841 AATTAATTAAAAAGTTAAATCTAAGACCTCAAACTATGAAACAGCTAAAAGAAAACATCGGGGAATCTCTCCAGGACATT 3921 GGAGTGGGCAAAGATTTCTTGTGTAATACCTGACAAACAGGCAACCAAAGCAAAAGTGGACAAATGGGATCACATCAAGT 4001 TAAAAATCTTCTGCATTGCAAAGGAAATAACAAAGTGAAGAGACAACCCATAGAATGTGAGATAATATTTGCAAACTATC 4081 CATCTGTATTAGGCCATTTTTGAAGTACTACAAAGAAATACTTGAGACTGAGTAATTTATAAAGAAGAGGTTTAATTGGC 4161 TCACGGTTTTGCAGGCTGTACAGGAAGCATGGTGCTAACATCTGATCAGCTTGTAGGGAGGCATCAGGAAGTTTCCAACC 4241 ATGGTGGAAGGCAAAAGGGGAATAAGTATCTCACATGGCAGGTGCAGGGCAAAGAGAGGGGGGAAGGGAAGTGCCACACA 4321 ACCAGATCTTGTGAGTACTCAGATTTTGTGAGGGGTGCTTGAGGTCATGGATACCCATTTACCCTGATGTGTTTATACAC 4401 ATTTCATACCTGTATTAAAATATCTCATGTACCCCATAAACATATACACCTACTTTGTACCCACAAAAATTTAAAAATAA 4481 AGTTAATTTCAATGTTTAAAGACTTGTTATTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | BC-1 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM796037. RNA binding protein: AGO2. Condition:4-Thiouridine
PAR-CLIP data was present in GSM796038. RNA binding protein: AGO2. Condition:4-Thiouridine
... - Gottwein E; Corcoran DL; Mukherjee N; et al., 2011, Cell host & microbe. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Gottwein E; Corcoran DL; Mukherjee N; et al. - Cell host & microbe, 2011
Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV) and frequently also harbors Epstein-Barr virus (EBV). The expression of KSHV- and EBV-encoded microRNAs (miRNAs) in PELs suggests a role for these miRNAs in latency and lymphomagenesis. Using PAR-CLIP, a technology which allows the direct and transcriptome-wide identification of miRNA targets, we delineate the target sites for all viral and cellular miRNAs expressed in PEL cell lines. The resulting data set revealed that KSHV miRNAs directly target more than 2000 cellular mRNAs, including many involved in pathways relevant to KSHV pathogenesis. Moreover, 58% of these mRNAs are also targeted by EBV miRNAs, via distinct binding sites. In addition to a known viral analog of cellular miR-155, we show that KSHV encodes a viral miRNA that mimics cellular miR-142-3p function. In summary, this study identifies an extensive list of KSHV miRNA targets, which are likely to influence viral replication and pathogenesis.
LinkOut: [PMID: 22100165]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293S |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
HITS-CLIP data was present in GSM1084076. RNA binding protein: AGO2. Condition:CLIP_nohippuristanol_rep1_SigmaAb
... - Karginov FV; Hannon GJ, 2013, Genes & development. |
Article |
- Karginov FV; Hannon GJ - Genes & development, 2013
When adapting to environmental stress, cells attenuate and reprogram their translational output. In part, these altered translation profiles are established through changes in the interactions between RNA-binding proteins and mRNAs. The Argonaute 2 (Ago2)/microRNA (miRNA) machinery has been shown to participate in stress-induced translational up-regulation of a particular mRNA, CAT-1; however, a detailed, transcriptome-wide understanding of the involvement of Ago2 in the process has been lacking. Here, we profiled the overall changes in Ago2-mRNA interactions upon arsenite stress by cross-linking immunoprecipitation (CLIP) followed by high-throughput sequencing (CLIP-seq). Ago2 displayed a significant remodeling of its transcript occupancy, with the majority of 3' untranslated region (UTR) and coding sequence (CDS) sites exhibiting stronger interaction. Interestingly, target sites that were destined for release from Ago2 upon stress were depleted in miRNA complementarity signatures, suggesting an alternative mode of interaction. To compare the changes in Ago2-binding patterns across transcripts with changes in their translational states, we measured mRNA profiles on ribosome/polysome gradients by RNA sequencing (RNA-seq). Increased Ago2 occupancy correlated with stronger repression of translation for those mRNAs, as evidenced by a shift toward lighter gradient fractions upon stress, while release of Ago2 was associated with the limited number of transcripts that remained translated. Taken together, these data point to a role for Ago2 and the mammalian miRNAs in mediating the translational component of the stress response.
LinkOut: [PMID: 23824327]
|
CLIP-seq Support 1 for dataset GSM4903833 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_a |
Location of target site | NM_001178101 | 3UTR | CCAGAAAACUUUAACAU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM4903834 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_b |
Location of target site | NM_001178101 | 3UTR | AUGAAAAAAAUGGAUACAUUAGGAGCUUCAAACACAUAUAAUUUCUCAAGAAAUUUCCAGAU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 3 for dataset GSM4903835 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / CTL_TD_21_c |
Location of target site | NM_001007094 | 3UTR | CAGAAAACUUUAACAU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 4 for dataset GSM4903836 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / 124_TD_21_a |
Location of target site | NM_001178101 | 3UTR | AGAAAACUUUAACAU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 5 for dataset GSM4903837 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / 124_TD_21_b |
Location of target site | NM_001178101 | 3UTR | CAGAAAACUUUAACAU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 6 for dataset GSM4903838 | |
---|---|
Method / RBP | HITS-CLIP / AGO |
Cell line / Condition | Dermal fibroblasts / 124_TD_21_c |
Location of target site | NM_001178101 | 3UTR | CAGAAAACUUUAACAU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Accession Series | GSE161239 |
CLIP-seq Viewer | Link |
CLIP-seq Support 7 for dataset GSM1084076 | |
---|---|
Method / RBP | HITS-CLIP / AGO2 |
Cell line / Condition | HEK293S / CLIP_nohippuristanol_rep1_SigmaAb |
Location of target site | ENST00000361085.5 | 3UTR | GCAAAUCACCUGAGGUCAGGAGUU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23824327 / GSE44404 |
CLIP-seq Viewer | Link |
CLIP-seq Support 8 for dataset GSM796037 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-1 / 4-Thiouridine |
Location of target site | ENST00000361085.5 | 3UTR | UCAAGAAAUUUCCAGA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
CLIP-seq Support 9 for dataset GSM796038 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-1 / 4-Thiouridine |
Location of target site | ENST00000361085.5 | 3UTR | UCAAGAAAUUUCCAGA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
75 hsa-miR-1299 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT079552 | VAMP3 | vesicle associated membrane protein 3 | 2 | 2 | ||||||||
MIRT154885 | GNAS | GNAS complex locus | 2 | 4 | ||||||||
MIRT275056 | SESN2 | sestrin 2 | 2 | 4 | ||||||||
MIRT303051 | B3GNT2 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 | 2 | 4 | ||||||||
MIRT319158 | CCDC71L | coiled-coil domain containing 71 like | 2 | 2 | ||||||||
MIRT339620 | TMPO | thymopoietin | 2 | 2 | ||||||||
MIRT441961 | BACE2 | beta-site APP-cleaving enzyme 2 | 2 | 2 | ||||||||
MIRT445113 | DCAF4 | DDB1 and CUL4 associated factor 4 | 2 | 2 | ||||||||
MIRT445290 | CD274 | CD274 molecule | 2 | 2 | ||||||||
MIRT446037 | HMCN1 | hemicentin 1 | 2 | 2 | ||||||||
MIRT446162 | C8A | complement C8 alpha chain | 2 | 2 | ||||||||
MIRT446175 | ZNF37A | zinc finger protein 37A | 2 | 4 | ||||||||
MIRT446414 | OCA2 | OCA2 melanosomal transmembrane protein | 2 | 2 | ||||||||
MIRT446884 | TRIM25 | tripartite motif containing 25 | 2 | 2 | ||||||||
MIRT449789 | C1orf109 | chromosome 1 open reading frame 109 | 2 | 2 | ||||||||
MIRT450026 | EHD3 | EH domain containing 3 | 2 | 2 | ||||||||
MIRT450367 | ADAMTS5 | ADAM metallopeptidase with thrombospondin type 1 motif 5 | 2 | 2 | ||||||||
MIRT479739 | CCND1 | cyclin D1 | 2 | 2 | ||||||||
MIRT484809 | ZNFX1 | zinc finger NFX1-type containing 1 | 2 | 2 | ||||||||
MIRT485892 | ZFP36 | ZFP36 ring finger protein | 2 | 2 | ||||||||
MIRT486036 | UBBP4 | ubiquitin B pseudogene 4 | 2 | 2 | ||||||||
MIRT488295 | DHCR24 | 24-dehydrocholesterol reductase | 2 | 2 | ||||||||
MIRT497377 | METTL8 | methyltransferase like 8 | 2 | 2 | ||||||||
MIRT508219 | ZNF850 | zinc finger protein 850 | 2 | 6 | ||||||||
MIRT510923 | PRRX1 | paired related homeobox 1 | 2 | 4 | ||||||||
MIRT512661 | STEAP3 | STEAP3 metalloreductase | 2 | 2 | ||||||||
MIRT520031 | YOD1 | YOD1 deubiquitinase | 2 | 6 | ||||||||
MIRT528490 | AGTR2 | angiotensin II receptor type 2 | 2 | 2 | ||||||||
MIRT530083 | PAGR1 | PAXIP1 associated glutamate rich protein 1 | 2 | 4 | ||||||||
MIRT531086 | CCDC140 | coiled-coil domain containing 140 | 2 | 2 | ||||||||
MIRT535363 | PEX5L | peroxisomal biogenesis factor 5 like | 2 | 2 | ||||||||
MIRT535595 | NUDT21 | nudix hydrolase 21 | 2 | 2 | ||||||||
MIRT538613 | CCT5 | chaperonin containing TCP1 subunit 5 | 2 | 4 | ||||||||
MIRT539002 | AVL9 | AVL9 cell migration associated | 2 | 2 | ||||||||
MIRT545918 | ZC3H4 | zinc finger CCCH-type containing 4 | 2 | 2 | ||||||||
MIRT548482 | EEF2 | eukaryotic translation elongation factor 2 | 2 | 2 | ||||||||
MIRT555088 | PURB | purine rich element binding protein B | 2 | 2 | ||||||||
MIRT561421 | TRIB3 | tribbles pseudokinase 3 | 2 | 2 | ||||||||
MIRT564965 | WTAP | WT1 associated protein | 2 | 2 | ||||||||
MIRT571686 | RPRD2 | regulation of nuclear pre-mRNA domain containing 2 | 2 | 2 | ||||||||
MIRT574656 | KLHL15 | kelch like family member 15 | 2 | 2 | ||||||||
MIRT610037 | CNOT6 | CCR4-NOT transcription complex subunit 6 | 2 | 6 | ||||||||
MIRT612436 | SMOC2 | SPARC related modular calcium binding 2 | 2 | 2 | ||||||||
MIRT614349 | LOH12CR1 | BLOC-1 related complex subunit 5 | 2 | 2 | ||||||||
MIRT615304 | CCDC158 | coiled-coil domain containing 158 | 2 | 2 | ||||||||
MIRT615771 | FSD2 | fibronectin type III and SPRY domain containing 2 | 2 | 2 | ||||||||
MIRT615889 | MT1A | metallothionein 1A | 2 | 2 | ||||||||
MIRT619147 | ZNF326 | zinc finger protein 326 | 2 | 2 | ||||||||
MIRT622042 | SSBP2 | single stranded DNA binding protein 2 | 2 | 2 | ||||||||
MIRT637385 | R3HDM2 | R3H domain containing 2 | 2 | 2 | ||||||||
MIRT640739 | EPB41 | erythrocyte membrane protein band 4.1 | 2 | 2 | ||||||||
MIRT644418 | PIGS | phosphatidylinositol glycan anchor biosynthesis class S | 2 | 2 | ||||||||
MIRT647638 | FAIM2 | Fas apoptotic inhibitory molecule 2 | 2 | 2 | ||||||||
MIRT654305 | RBMS3 | RNA binding motif single stranded interacting protein 3 | 2 | 2 | ||||||||
MIRT654367 | RBM23 | RNA binding motif protein 23 | 2 | 2 | ||||||||
MIRT655944 | NDST1 | N-deacetylase and N-sulfotransferase 1 | 2 | 2 | ||||||||
MIRT655990 | MYRF | myelin regulatory factor | 2 | 2 | ||||||||
MIRT659692 | CD226 | CD226 molecule | 2 | 2 | ||||||||
MIRT665868 | TIAF1 | TGFB1-induced anti-apoptotic factor 1 | 2 | 2 | ||||||||
MIRT667317 | MYO18A | myosin XVIIIA | 2 | 2 | ||||||||
MIRT684312 | GTF3C4 | general transcription factor IIIC subunit 4 | 2 | 2 | ||||||||
MIRT694138 | CYP27C1 | cytochrome P450 family 27 subfamily C member 1 | 2 | 2 | ||||||||
MIRT698529 | TFRC | transferrin receptor | 2 | 2 | ||||||||
MIRT698834 | SSR2 | signal sequence receptor subunit 2 | 2 | 2 | ||||||||
MIRT700657 | PPP1R11 | protein phosphatase 1 regulatory inhibitor subunit 11 | 2 | 2 | ||||||||
MIRT705377 | ATP1B3 | ATPase Na+/K+ transporting subunit beta 3 | 2 | 2 | ||||||||
MIRT707314 | TMEM184B | transmembrane protein 184B | 2 | 2 | ||||||||
MIRT709027 | KBTBD13 | kelch repeat and BTB domain containing 13 | 2 | 2 | ||||||||
MIRT716032 | TMPRSS4 | transmembrane protease, serine 4 | 2 | 2 | ||||||||
MIRT718228 | LCE1A | late cornified envelope 1A | 2 | 2 | ||||||||
MIRT718475 | TMEM151A | transmembrane protein 151A | 2 | 2 | ||||||||
MIRT722333 | BEND6 | BEN domain containing 6 | 2 | 2 | ||||||||
MIRT734096 | TUG1 | taurine up-regulated 1 (non-protein coding) | 3 | 0 | ||||||||
MIRT734099 | NOTCH3 | notch 3 | 3 | 0 | ||||||||
MIRT755871 | LIF | LIF, interleukin 6 family cytokine | 4 | 1 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|